Oragenics Announces Conversion Of Preferred Shares And Elimination Of Liquidation Preference; The Conversion Helps Simplify The Co's Capital Structure And Eliminates ~$2.35M In Liquidation Preference, Effectively Removing A Significant Overhang On The Company's Stock

Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the conversion of its remaining outstanding convertible Series A and Series B Preferred Shares into common stock. The conversion helps simplify the company's capital structure and eliminates approximately $2.35 million in liquidation preference, effectively removing a significant overhang on the company's stock.

Holders of the Company's remaining 5,417,000 Series A Preferred Shares and 4,050,000 Series B Preferred Shares exercised their right to convert their shares into a total of approximately 22,000 common shares. The Series A and B Preferred Shares, which carried no voting rights, have now been fully retired.